Literature DB >> 23748106

Hepatocellular carcinoma: transcriptome diversity regulated by RNA editing.

Yan Li1, Leilei Chen, Tim Hon Man Chan, Xin-Yuan Guan.   

Abstract

Hepatocellular carcinoma (HCC) can be envisioned as a prolonged multi-stage process accumulating genetic and epigenetic changes. In the past years, DNA alterations lent us important clues to the comprehension of molecular pathways involved in HCC. However, as an increasing number of RNAs were identified to be subject to A-to-I modifications, it has become apparent that RNA editing might be the causal basis of various human diseases. Recent evidence has strengthened this notion by correlating hyper-edited AZIN1 (antizyme inhibitor 1) protein with HCC onset and the mechanisms that regulate cell transformation. As we continue to demystify it, RNA editing astonishes us with its diverse substrates, esoteric functions, elaborate machinery and complex interaction with HBV/HCV viral infection. In this review, we examine the contribution of A-to-I RNA editing to caner onset/progression and explore its potential implications for cancer treatment advances.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  A-to-I RNA editing; ADARs; AZIN1; HCC; Transcriptome

Mesh:

Substances:

Year:  2013        PMID: 23748106     DOI: 10.1016/j.biocel.2013.05.033

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  9 in total

1.  Studied microRNA gene expression in human hepatocellular carcinoma by microRNA microarray techniques.

Authors:  Jian-Xiang Niu; Xing-Kai Meng; Jian-Jun Ren
Journal:  World J Gastroenterol       Date:  2015-11-28       Impact factor: 5.742

2.  Association between two common polymorphisms and risk of hepatocellular carcinoma: evidence from an updated meta-analysis.

Authors:  Zhaoming Wang; Lei Zhang; Xuesong Shi; Huayu Xu; Ting Wang; Jianmin Bian
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

3.  Detection of canonical A-to-G editing events at 3' UTRs and microRNA target sites in human lungs using next-generation sequencing.

Authors:  Ramani Soundararajan; Timothy M Stearns; Anthony L Griswold; Arpit Mehta; Alexander Czachor; Jutaro Fukumoto; Richard F Lockey; Benjamin L King; Narasaiah Kolliputi
Journal:  Oncotarget       Date:  2015-11-03

4.  RNA editing signature during myeloid leukemia cell differentiation.

Authors:  C Rossetti; E Picardi; M Ye; G Camilli; A M D'Erchia; L Cucina; F Locatelli; L Fianchi; L Teofili; G Pesole; A Gallo; R Sorrentino
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

5.  Epitranscriptomic profiling across cell types reveals associations between APOBEC1-mediated RNA editing, gene expression outcomes, and cellular function.

Authors:  Violeta Rayon-Estrada; Dewi Harjanto; Claire E Hamilton; Yamina A Berchiche; Emily Conn Gantman; Thomas P Sakmar; Karen Bulloch; Khatuna Gagnidze; Sheila Harroch; Bruce S McEwen; F Nina Papavasiliou
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-22       Impact factor: 11.205

6.  Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma.

Authors:  Zhu-qing Zhang; Hua Meng; Nan Wang; Li-na Liang; Li-na Liu; Shu-ming Lu; Yong Luan
Journal:  Diagn Pathol       Date:  2014-07-02       Impact factor: 2.644

Review 7.  The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update.

Authors:  Ming Liu; Lingxi Jiang; Xin-Yuan Guan
Journal:  Protein Cell       Date:  2014-06-11       Impact factor: 14.870

8.  MicroRNA-132 suppresses migration and invasion of renal carcinoma cells.

Authors:  Yi Yu; Wenbao Lu; Xinmin Zhou; Hua Huang; Shaochen Shen; Lian Guo
Journal:  J Clin Lab Anal       Date:  2019-10-17       Impact factor: 2.352

Review 9.  The Role of the Z-DNA Binding Domain in Innate Immunity and Stress Granules.

Authors:  De Chen Chiang; Yan Li; Siew Kit Ng
Journal:  Front Immunol       Date:  2021-02-03       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.